Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company dedicated to discovering, developing, and delivering potentially curative therapies that address the underlying causes of heart disease. Founded in 2016 and headquartered in South San Francisco, Tenaya Therapeutics leverages its integrated platforms in Gene Therapy, Cellular Regeneration, and Precision Medicine to advance a pipeline of novel therapeutic candidates targeting both rare genetic cardiovascular disorders and more prevalent heart conditions.
Tenaya's flagship programs include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF). In late October 2023, the company announced the U.S. FDA clearance of its Investigational New Drug (IND) application for TN-401, initiating the RIDGE-1 Phase 1b clinical trial to evaluate its safety, tolerability, and efficacy.
Tenaya is a preclinical-stage company but has made significant strides. Its gene therapy TN-401 aims to treat ARVC by delivering a fully functional PKP2 gene to restore protein levels necessary for heart muscle function. The company also focuses on genetic mutations responsible for heart diseases, aiming to reverse or halt disease progression efficiently.
The company’s commitment to innovation extends to its robust pipeline and strategic collaborations, ensuring progress in addressing unmet needs in cardiac care. With a fully operational Genetic Medicines Manufacturing Center, Tenaya can produce clinical trial material at scale, highlighting its readiness to transition groundbreaking research into clinical applications.
For the latest updates, detailed financial results, and corporate announcements, visit their official website at www.tenayatherapeutics.com.
Tenaya Therapeutics (NASDAQ: TNYA) announced two key appointments: Karah Parschauer to its Board of Directors and Joanna Auch as Senior VP of People and Culture. These appointments aim to strengthen Tenaya's leadership amid its transition to a public company with over 100 employees. CEO Faraz Ali highlighted that both individuals bring valuable experience and will enhance the company's capabilities in drug development for heart disease. Parschauer has extensive biopharmaceutical experience and previously held roles at Ultragenyx, while Auch has over 15 years in HR.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced significant changes to its Board of Directors, with the appointment of Dr. June Lee, who brings extensive experience in cardiovascular drug development. Dr. Lee was previously the Founder and CEO of Esker Therapeutics and held senior roles at MyoKardia and Genentech. She succeeds Dr. JJ Kang, who steps down after five years to focus on other ventures. The move reflects Tenaya's evolution towards becoming a clinical-stage company as it aims to advance therapies for heart disease.
Tenaya Therapeutics (NASDAQ: TNYA), a biotechnology firm focused on heart disease therapies, announces CEO Faraz Ali's participation in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2. A fireside chat webcast will be available starting November 22, 2021, at 10:00 a.m. ET. Founded by top cardiovascular scientists, Tenaya is dedicated to developing innovative treatments for both rare and common heart conditions through Gene Therapy, Cellular Regeneration, and Precision Medicine.
Tenaya Therapeutics, a biotechnology firm, reported significant advancements in its gene therapy programs and third quarter 2021 financial results. The company initiated a global natural history study for children with MYBPC3 mutations to enhance the TN-201 gene therapy development. Preclinical data demonstrated promising outcomes in murine models, highlighting durability in disease reversal. Tenaya's cash position stands strong at $280.5 million post-IPO, expected to sustain operations through late 2023. Despite a net loss of $18.3 million, the company continues its progress towards clinical-stage development.
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in multiple key biotechnology conferences in October. Events include the Chardan 5th Annual Genetic Medicines Conference on October 4, featuring a panel discussion and a fireside chat. Ali will also speak at the Alliance for Regenerative Medicine’s Cell and Gene Meeting on October 13, followed by a company presentation. Lastly, he will present at the Jefferies Gene Therapy/Editing Summit on October 28. Tenaya focuses on innovative therapies for heart disease.
Tenaya Therapeutics (TNYA) announced significant developments, including the granting of Orphan Drug Designation for its TN-201 gene therapy for genetic HCM by the FDA. The company successfully completed its IPO on August 3, 2021, raising $207 million. Leadership changes include Leone Patterson as Chief Financial Officer and Matt Pollman as SVP of Clinical Development. Financial results for Q2 2021 show a net loss of $15.2 million and R&D expenses of $10.9 million. Tenaya anticipates submitting IND applications for TN-201 and TYA-11631 in 2022.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology firm focused on heart disease therapies, announced that CEO Faraz Ali will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 2:45 p.m. ET. The company's mission is to develop curative therapies addressing heart disease's underlying causes through gene therapy, cellular regeneration, and precision medicine. Founded by top cardiovascular scientists, Tenaya aims to tackle both rare genetic disorders and more common heart conditions.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has successfully closed its upsized initial public offering, selling 13,800,000 shares at $15.00 each, totaling gross proceeds of $207.0 million. This offering included the full exercise of underwriters' options for 1,800,000 additional shares. Shares began trading on the Nasdaq Global Select Market on July 30, 2021. Morgan Stanley, Cowen, and Piper Sandler served as joint book-running managers, with Chardan leading the offering. The registration statements for this IPO were effective as of July 29, 2021.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) has announced the pricing of its upsized initial public offering (IPO) of 12 million shares at $15.00 each, set to trade on the Nasdaq from July 30, 2021. The IPO is expected to generate gross proceeds of $180 million, with an option for underwriters to purchase an additional 1.8 million shares. The offering closes on August 3, 2021, pending usual conditions, with Morgan Stanley, Cowen, and Piper Sandler as joint book-running managers. Tenaya aims to develop therapies for heart disease, leveraging expertise from top scientific institutions.
FAQ
What is the current stock price of Tenaya Therapeutics (TNYA)?
What is the market cap of Tenaya Therapeutics (TNYA)?
What is Tenaya Therapeutics, Inc.?
What is TN-401?
When was Tenaya Therapeutics established?
What are the main therapeutic programs of Tenaya Therapeutics?
Where is Tenaya Therapeutics located?
What recent milestones has Tenaya Therapeutics achieved?
What is the goal of TN-301?
How is Tenaya Therapeutics advancing its therapies?
What is the significance of the RIDGE-1 Phase 1b clinical trial?
How can I get more information about Tenaya Therapeutics?
